Evidence map›Paper›PMID 41018051›Full record

ArticleJournal of the Endocrine Society2025

MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression.

Raisa Ghosh, Dilara Akbulut, William F Simonds, Lee S Weinstein, Samira M Sadowski, Jenny E Blau, Martha Quezado, Sunita K Agarwal, Smita Jha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raisa GhoshMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Dilara AkbulutSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
William F SimondsMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID https://orcid.org/0000-0001-7806-706X
Lee S WeinsteinMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Samira M SadowskiSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jenny E BlauMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Martha QuezadoSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Sunita K AgarwalMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Smita JhaMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID https://orcid.org/0000-0001-9201-3340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Approximately 50% to 70% of patients with multiple endocrine neoplasia type 1 (MEN1) die of duodenopancreatic neuroendocrine tumors (NETs). While c-MET inhibitors in combination with antivascular endothelial growth factor therapy have been shown to result in longer progression-free survival in patients with sporadic NETs, data regarding their efficacy in patients with MEN1-related NETs are lacking. Objective: We sought to characterize c-MET expression in MEN1-related NETs and evaluate its association with clinicopathologic characteristics. Methods: Forty-three tumors from 22 genetically confirmed patients with MEN1-related metastatic NETs were identified. Of these, 15 of 22 (68%) patients had distant metastases while the remaining 7 of 22 had locoregional metastases. Results: c-MET expression was assessed in these tumors via immunohistochemistry. A total of 19 of 43 (44%) were primary tumors (duodenum, pancreas, stomach) while the remaining were metastases. c-MET expression was scored as strongly positive in 3 of 43 (H-score >50), weakly positive in 6 of 43 (H-score: 10-50), and negative in 34 of 43 (H-score <10) tumors. All 3 tumors with strong positive c-MET expression were from patients with a distinctly aggressive clinical course. The 6 tumors with weakly positive c-MET expression were from patients with stable disease, including 4 with distant metastases. Of the 13 patients with all tumors negative for c-MET expression, all but 1 had stable disease. Age at initial NET diagnosis; tumor site, type or grade; number of sites of distant metastases; total number of surgeries for NETs; or the stability of overall tumor burden did not predict c-MET expression. Conclusion: Our findings suggest a role for c-MET inhibition in personalizing therapy for patients with MEN1-related NETs.

Indexed as

dpNETgastrinomaGEP-NETsMET-inhibitorspancreatic NETs

Identifiers

PMID41018051
PMCPMC12464676

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.